End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,76,200 KRW | -0.62% | -2.06% | -12.56% |
24/05 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
10/05 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Sales 2024 * | 3,485B 2.53B 211B | Sales 2025 * | 4,155B 3.02B 251B | Capitalization | 36,261B 26.36B 2,191B |
---|---|---|---|---|---|
Net income 2024 * | 540B 393M 32.63B | Net income 2025 * | 1,100B 800M 66.47B | EV / Sales 2024 * | 10.6 x |
Net Debt 2024 * | 721B 524M 43.57B | Net cash position 2025 * | 106B 76.71M 6.38B | EV / Sales 2025 * | 8.7 x |
P/E ratio 2024 * |
69.5
x | P/E ratio 2025 * |
33.9
x | Employees | 2,034 |
Yield 2024 * |
0.25% | Yield 2025 * |
0.27% | Free-Float | 66.01% |
1 day | -0.62% | ||
1 week | -2.06% | ||
1 month | -6.03% | ||
3 months | -1.95% | ||
6 months | +8.03% | ||
Current year | -12.56% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 24/07/24 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 08/14/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.14% | 2 M€ | -14.14% | ||
0.99% | 11 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 1,76,200 | -0.62% | 882,885 |
30/24/30 | 1,77,300 | -0.89% | 357,482 |
29/24/29 | 1,78,900 | -1.11% | 493,642 |
28/24/28 | 1,80,900 | +0.72% | 411,965 |
27/24/27 | 1,79,600 | -0.17% | 401,269 |
End-of-day quote Korea S.E., May 31, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.56% | 26.22B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B | |
-3.38% | 9.6B |
- Stock Market
- Equities
- A068270 Stock